Webb13 feb. 2024 · HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used … Webb13 feb. 2024 · It is assumed that adjuvant HIPEC will reduce the expected absolute risk of peritoneal recurrence from 36% to 18% at 36 months for T4 colon-rectal carcinoma. BackgroundLocal relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection …
ESMO Congress OncologyPRO
Webb9 sep. 2024 · ESMO 2024: Live PLUS event. The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and … WebbHIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during … ian chewe facebook
Prophylactic surgery plus hyperthermic intraperitoneal …
Webb18 feb. 2024 · Alvaro Arjona-Sanchez, ESMO 2024: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer Watch Time: 4 mins. Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. WebbHIPECT4 shows that HIPEC with MMC in effective and safe to prevent peritoneal relapse in T4 colorectal cancer, presented in @myESMO 2024. #hospitalreinasofia… 35 comments on LinkedIn WebbThis is what has been done in HIPECT4 trial which has recently completed its accrual in Spain . Also, mitomycin C alone is to be used in the CATCH trial not yet activated in the USA, a modification which is appealing because the HIPEC utilizes a doublet rather than monotherapy—mitomycin C and cisplatin HIPEC. ian chesterton tardis wiki